生物製药第三方物流市场按服务类型、温度范围、运输方式、最终用户、产品类型和包装类型划分－全球预测，2025-2032年

预计到 2032 年，生物製药第三方物流市场规模将达到 3,642.3 亿美元，复合年增长率为 14.67%。

关键市场统计数据
基准年 2024	1217.7亿美元
预计年份：2025年	1400.3亿美元
预测年份 2032	3642.3亿美元
复合年增长率 (%)	14.67%

专业化的物流能力对于维护生物製药产品的完整性以及促进其进入市场至关重要。

生物製药的生命週期越来越依赖专业的第三方物流能力，以维护产品完整性、确保合规性并加快时间紧迫的交付。随着先进疗法、温度敏感型生技药品和复杂供应链的激增，相关人员必须应对由技术创新、监管和不断变化的贸易动态所构成的复杂局面。

本报告综合分析了物流物流及其客户在科学研究、临床和商业管道中的营运现状和策略曲折点。报告探讨了服务设计、温度控制、运输方式、包装复杂性和终端用户需求如何检验，从而影响营运重点。分析重点指出，供应商可以透过能力投资、流程标准化和风险规避来提升价值。

重要的是，本执行摘要旨在为高阶领导提供简洁而全面的观点，以指导其采购、网路设计和伙伴关係策略。透过重点阐述最重要的趋势和决策驱动因素，本出版物旨在推动有针对性的投资，从而在不影响品质或合规性的前提下，减少产品损耗、加快患者获取药物的速度并降低总体成本。

读者将获得切实可行的见解，以支持供应链、品质、监管和商业团队之间的跨职能协作，从而为物流相关人员在当今日益复杂的科学和监管环境中保持韧性和竞争力而必须做出的战略选择提供框架。

数位遥测、包装创新、生产重新分配以及日益严格的监管要求如何重新定义物流供应商的策略重点

由于技术成熟、监管环境调整以及生产布局变化，生物製药第三方物流正经历重大变革。数位化正从试点计划走向营运核心，即时远端检测、基于状态的异常管理和预测分析等技术能够实现主动干预，从而减少药品损耗并加快运输速度。

同时，包装创新正在重塑低温运输的经济格局。主动隔热包装解决方案，例如气调系统和先进的冷藏集装箱，正越来越多地与先进的被动隔热材料相结合，形成混合模式延长运输窗口期并减少对加急运输的依赖。这些技术进步与包装设计和运输规划的紧密结合相辅相成，优化了有效载荷密度并降低了单件货物的搬运风险。

另一个关键的转型方向是製造和供应节点的策略性重新配置。区域製造地的加速成长以及生物製药公司日益垂直化的趋势，正迫使物流供应商重新配置其网络，转向近岸外包和多节点配送。这种转变需要灵活的仓储布局，既要具备常温和冷藏仓储能力，又要提供支援快递空运、标准空运、海运和陆运等多种运输方式的解决方案。

监管审查日益严格，合规要求也从文件准确性扩展到端到端管理，包括数位化审核追踪和有效的温度控制系统。因此，能够展现出健全的品质系统、检验的流程和透明的监管链报告的供应商将赢得更高的信任度和市场青睐。简而言之，产业正朝着一个以技术能力、监管应对力和网路适应性决定市场主导的生态系统发展。

评估 2025 年关税调整如何刺激了对近岸外包、模式优化、海关专业知识增强以及整个生物製药供应链韧性的投资。

2025年美国贸易政策带来的关税调整累积效应正显着改变生物製药供应链的跨国流动与策略物流决策。关税导致的成本增加迫使许多製造商和物流合作伙伴重新评估筹资策略、库存状况和运输方案，以在遵守关税和贸易规则的同时维持利润率和服务水准。

直接后果之一是近岸外包之争愈演愈烈，各公司都在评估是否将部分生产过程转移至更靠近关键市场的地方，或在关键市场附近储备缓衝库存，以减轻关税导致的成本上涨的影响。这种战术性转变也对仓储策略产生下游影响，要求仓储策略具备灵活的合约条款以及在短时间内扩建冷藏和常温仓库的能力。

贸易壁垒也促使企业重新评估运输方式。当关税增加海运中间投入品或成品的到岸成本时，企业会透过将关键产品转向高成本但速度更快的空运来减轻影响；或者，企业也会优化容器化策略，透过合併货物数量来分摊关税，从而降低成本。这两种方法都需要加强包装设计和运输计画之间的协调，以确保运输过程中的温度完整性，同时兼顾每次运输的成本。

关税调整加剧了海关流程的复杂性和文件审查的严格程度，凸显了贸易合规专业知识在第三方物流中的重要性。能够提供报关代理、关税分类咨询和关税减免服务的供应商正日益获得策略价值。此外，关税波动也凸显了合约中关于转嫁成本、避险安排和服务水准调整条款的弹性的重要性。

除了成本管理之外，关税也在加速企业对供应链视觉性和情境规划的投资。如今，企业更加重视对分销网络进行压力测试，以应对不断上涨的关税，并模拟关税对前置作业时间、库存週转天数和低温运输连续性等营运方面的影响。这种对韧性的关注也推动了对以分析主导的咨询服务的需求，以及对双重采购、缓衝仓储和模组化运输能力的投资，这些能力可以根据贸易动态的变化进行重新部署。

一个详细的细分框架，揭示了服务类型、温度范围、运输方式、最终用户需求、产品类型和包装选择如何决定物流策略。

细分市场分析揭示了服务结构、温度控制要求、运输方式、终端用户画像、产品类型和包装选项如何相互交织，从而定义物流供应商的价值提案和营运重点。从服务类型角度检验，市场涵盖配送管理、包装和贴标、运输以及仓储。包装和贴标本身又分为主动式和被动式两种方法，其中主动式包装进一步细分为气调包装和冷藏集装箱。运输方式分为空运、铁路运输、公路运输和海运，空运提供快递和标准两种选择，以满足不同的紧急程度和成本需求。仓储业需要在常温储存和冷藏保管之间取得平衡，并且必须在经过检验的监控系统下运作。

温度区域划分是一项核心营运决策，因为常温、冷藏区、控温区和冷冻区在处理、监控和监管要求方面各不相同。在冷藏区，又可区分监控冷藏环境和标准冷藏环境；控温区也分为监控控温和标准控温；冷冻物流则分为标准製冷和超低温要求，后者通常需要专门的基础设施。

运输方式细分揭示了空运、铁路、道路运输和海运的选择如何影响运输时间、环境影响和包装需求。空运选项包括特快空运和标准空运，道路运输区分整车运输和零担运输模式，海运区分整箱运输和拼箱运输策略。这些运输方式的差异体现在整个分销网络的最佳包装和库存策略中。

生物製药生产商、契约製造组织、受託研究机构、诊断实验室以及医院/诊所各自对服务水准和监管要求各不相同。医院和诊所可细分为社区医院和研究型医院，它们的采购週期和临床风险接受度也存在差异。

依产品类型细分，可以明确细胞疗法、基因疗法、单株抗体、重组蛋白和疫苗的独特处理需求。细胞疗法必须细分为树突细胞疗法和干细胞疗法，二者对低温运输的要求各不相同。疫苗分为灭活疫苗和减毒疫苗，二者在稳定性、运输和监管要求上有差异。主动包装包括冷藏货柜和温控运输箱，而被动包装则使用保温箱和保温毯。这些细分维度共同构成了一个矩阵，该矩阵定义了第三方物流供应商的基础设施投资、人员培训和品质保证通讯协定。

美洲、欧洲、中东和非洲以及亚太地区的基础设施、管理体制和商业动态将如何推动差异化的网路设计和服务优先顺序的发展？

区域动态对网路设计和服务预期有显着影响，每个区域都呈现不同的营运、监管和商业考量。在美洲，作为创新中心，先进的低温运输基础设施和成熟的法规环境催生了对高频快递服务、高效冷藏仓库和综合海关服务的需求。区域贸易协定和国内製造业投资正在影响运输方式的选择和仓库选址，而商业客户则优先考虑关键治疗药物的快速补货和可扩展的温控仓库。

欧洲、中东和非洲的情况各不相同。在西欧，严格的法律规范以及成熟的多式联运路线促使供应商实施统一的品管系统和跨境低温运输解决方案。中东作为分销和转口枢纽，鼓励投资建造以转运为导向的仓库和可靠的航空连接。在非洲，基础设施和低温运输的挑战凸显了投资「最后一公里」解决方案、与当地产业营运商建立伙伴关係关係以及采用被动式包装以弥补冷藏能力不足的重要性。

亚太地区融合了高产量製造中心、快速成长的区域需求以及多元化的法规环境。东南亚和南亚部分地区正在加速扩建常温和冷藏仓库，而东北亚则继续推动对需要严格温控和快速运输的复杂生技药品的出口。在全部区域，物流供应商必须平衡对大型低温运输资产的投资与能够适应贸易流量、监管差异和季节性需求模式的灵活配送网络。

为什么市场领导能够透过结合数位化视觉性、完善的低温运输资产、监管专业知识以及灵活可扩展的商业模式而取得成功？

生物製药第三方物流领域的主要企业在多个方面展现出差异化优势，包括整合的数位化视觉性、检验的低温运输资产、法规和海关专业知识，以及能够适应临床和商业产品细微差别的灵活商业模式。市场领导者正在投资远端检测平台，以产生持续的状态资料并实现自动化异常管理，同时不断拓展地域布局，将库存部署在更靠近关键需求中心的位置。

策略伙伴关係和收购是快速获取特定领域能力（例如超冷储存或专业包装和工程）的常用途径。对于寻求降低风险的製造商和服务机构而言，能够将内部技术专长与可扩展的仓储规模和认证承运商网路结合的供应商极具提案。此外，将贸易合规和海关咨询纳入其服务组合的公司，能够帮助企业应对复杂的跨境物流，从而创造更多价值。

卓越营运仍然是企业脱颖而出的关键。那些能够跨区域标准化流程、检验包装和运输方案并维护严格文件记录的公司，可以缩短监管检查和审核期间的等待时间。物流供应商可以提供模组化服务，从专用冷藏库到託管配送方案，从而满足从委外研发机构到大型生物製药生产商等各类组织的需求。最终，商业性成功与能否将技术能力转化为可预测、审核的服务绩效密切相关。

为物流领导者提供切实可行的、具有重大影响力的行动方案，以提高透明度、优化包装策略、重新设计弹性网络，并将贸易合规性融入他们的服务产品中。

产业领导者应优先采取一系列切实可行的措施，为生物製药产业建立一个稳健、合规且经济高效的第三方物流能力。首先，投资建造一个端到端的视觉化系统，该系统能够提供即时远端检测、自动异常警报和整合彙报功能，从而满足营运需求和监管要求。这样的系统可以减少产品损失，并在偏差时支援快速决策。

其次，采用结合被动和主动解决方案的多层包装策略，在确保产品完整性的同时优化成本。透过根据运输方式和温度敏感性选择合适的包装，企业可以延长交货期限，而无需总是依赖对时间要求严格的空运。这种方法应透过遵循主导通讯协定的合格测试进行检验。

第三，重新评估网路拓扑结构，并在适当情况下采用近岸外包或多节点分散部署。降低跨境风险，并将缓衝库存放置在更靠近需求的位置，从而降低海关风险并缩短前置作业时间。但是，网路重新设计必须与服务提供者保持合约弹性，并制定应对容量限制的紧急时应对计画。

第四，将贸易合规和海关咨询服务整合到物流伙伴关係中，以便主动管理关税影响和归类风险。提供这些服务的供应商可以显着减轻客户的行政负担，并提高到岸成本管理的可预测性。

最后，我们开发了一套模组化的商业服务方案，能够快速实现从临床到商业的扩展，满足超低温储存需求，并为高风险产品类别提供专属的客户成功资源。将商业性奖励与服务可靠性结合，有助于促进协作解决问题和建立长期伙伴关係。

采用严谨的混合方法研究途径，结合从业者访谈、营运案例审查、选择性二次综合和专家交叉检验，以获得实际的物流见解。

本分析所依据的研究采用了多种方法，结合了初步访谈、二手文献综述和营运案例分析，以确保研究结果的稳健性和有效性。初步研究包括对供应链和品质管理人员、物流人员、包装工程师和监管专家进行结构化访谈，这些访谈有助于对能力差距和新兴实践进行定性评估。这些访谈构成了跨服务类型和区域的情境分析和风险映射的基础。

为了阐明技术采纳模式、监管发展和运输方式成本动态，我们选择性地参考了二手资料。透过对营运案例的分析，我们深入了解了包装合格、低温运输故障和改进策略，从而能够识别可复製的缓解措施和最佳实践。我们优先考虑经过检验的案例，而非轶事，并参考多位独立从业者的证词来交叉验证相关论点。

此分析方法严谨，包括对网路和包装假设进行敏感度测试，以及由在生物製药物流运营方面拥有实务经验的专家进行同侪审查。该分析避免了推测性的预测，而是专注于经验法则趋势、观察到的行为以及对采购和营运团队的实际意义。

研究着重于定性和操作性洞察，而非专有的商业性指标。研究建议在适当情况下可根据具体情况进行调整，鼓励各组织在进行大规模实施前进行局部检验和成本效益分析。

本文综合阐述了经过检验的低温运输能力、适应性强的网路以及内建的贸易合规性为何能够决定竞争优势和营运韧性。

技术创新、监管趋严以及贸易格局的变化，共同加速了生物製药第三方物流的发展。那些拥有先进遥测技术、检验的包装生态系统以及深厚的监管和海关专业知识的先进包装公司，最有可能满足这个产品特性复杂、服务期望高的市场需求。在这种环境下，低温运输营运的卓越战术性能够直接转化为製造商和医疗服务提供者的策略价值。

重新利用仓库空间、调整运输方式以及提供模组化服务包的能力，能够帮助企业快速应对需求激增和政策变化。将贸易合规融入核心服务的企业，尤其是在关税和跨境复杂性不断涌现的情况下，将能够减少摩擦并获得竞争优势。

最后，最成功的物流合作伙伴是那些实践持续改善的合作伙伴。透过将洞察转化为有效的流程和可衡量的绩效，物流供应商可以减少浪费，加快患者获得药物的速度，并支持日益先进的生物製药疗法的更广泛商业化途径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 推出人工智慧驱动的即时温度监测解决方案，以确保低温运输物流过程中的生物稳定性
• 扩建符合GDP标准的专用设施，以支援细胞和基因治疗的储存和分发需求
• 运用数位双胞胎技术进行建模，预测复杂生物製药供应链中的中断
• 透过将第三方物流供应商与监管机构连接起来，简化序列化和追踪合规性流程
• 建构集空运、海运和陆运于一体的多式联运网络，以优化全球低温运输效率
• 投资永续低温运输包装解决方案，以减少碳排放并保持产品在远距运输过程中的完整性
• 部署基于区块链的平台，以提高生技药品来源和温度偏差追踪的透明度
• 对整合物联网感测器和云端分析技术的端到端可视性平台的需求日益增长，该平台可用于温度敏感型货物的运输。
• 针对mRNA疫苗分发，量身订做的「最后一公里」配送策略伙伴关係，以满足医院和临床试验的需求。
• 按需仓储模式的成长为生物製药分销网络提供可扩展的容量和灵活的租赁条款

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 生物製药第三方物流市场（依服务类型划分）

• 分销管理
• 包装和标籤
  • 活性包装
    • CA包装
    • 冷藏货柜
  • 标籤服务
  • 被动式封装
• 运输
  • 空运
    • 航空快运
    • 标准航空公司
  • 铁路运输
  • 道路运输
  • 海上运输
• 仓库
  • 常温仓库存储
  • 冷藏仓库存储

9. 生物製药第三方物流市场（依温度范围划分）

• 常温
• 冷藏
  • 用显示器降温
  • 标准冷藏
• 恆温
  • 恆温监控器
  • 标准恆温
• 冷冻
  • 标准冷冻
  • 超级冷冻

第十章 生物製药第三方物流市场（依运输方式划分）

• 空运
  • 航空快运
  • 标准航空公司
• 铁路货运
• 道路运输
  • 整车运输
  • 小批量卡车运输
• 海运
  • FCL
  • LCL

第十一章 生物製药第三会物流市场（以最终用户划分）

• 生物製药製造商
• CMO
• CRO
• 诊断实验室
• 医院和诊所
  • 社区医院
  • 研究医院

第十二章 生物製药第三方物流市场（依产品类型划分）

• 细胞治疗方法
  • 树突细胞疗法
  • 干细胞疗法
• 基因治疗
• 单株抗体
• 重组蛋白
• 疫苗
  • 惰性
  • 活病毒疫苗

第十三章 生技製药第三方物流市场（依包装类型划分）

• 活性包装
  • 冷藏货柜
  • 温控运输车
• 被动式封装
  • 保温箱
  • 保温毯

第十四章 生物製药第三会物流市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 生物製药第三方物流市场（依产业划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国生物製药第三方物流市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Kuehne+Nagel International AG
  • Deutsche Post AG
  • DSV Panalpina A/S
  • DB Schenker Logistics Germany AG & Co. KG
  • United Parcel Service, Inc.
  • FedEx Corporation
  • CEVA Logistics AG
  • Agility Public Warehousing Company KSCP
  • Bollore SE
  • Expeditors International of Washington, Inc.

The Biopharmaceutical Third Party Logistics Market is projected to grow by USD 364.23 billion at a CAGR of 14.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 121.77 billion
Estimated Year [2025]	USD 140.03 billion
Forecast Year [2032]	USD 364.23 billion
CAGR (%)	14.67%

An authoritative strategic overview highlighting why specialized logistics capabilities are mission-critical for preserving biopharmaceutical product integrity and enabling market access

The lifecycle of biopharmaceutical products increasingly depends on specialized third-party logistics capabilities that preserve integrity, ensure regulatory compliance, and expedite time-critical deliveries. As advanced therapies, temperature-sensitive biologics, and complex supply chains proliferate, stakeholders must navigate a landscape defined by technological innovation, regulatory scrutiny, and evolving trade dynamics.

This report synthesizes operational realities and strategic inflection points for logistics partners and their customers across research, clinical, and commercial channels. It examines how service design, temperature control, transportation modes, packaging sophistication, and end-user needs interact to shape operational priorities. The analysis highlights where providers can extract value through capability investment, process standardization, and risk mitigation.

Importantly, the executive summary is intended to equip senior leaders with a concise yet comprehensive perspective that informs procurement, network design, and partnership strategies. By foregrounding the most consequential trends and decision levers, this synthesis aims to catalyze targeted investments that reduce product loss, accelerate patient access, and improve total cost-to-serve without compromising quality or compliance.

Readers will find pragmatic insights that support cross-functional collaboration between supply chain, quality, regulatory, and commercial teams. The objective is to frame the strategic choices logistics stakeholders must make today to remain resilient and competitive in a sector where scientific and regulatory complexity continue to rise.

How digital telemetry, packaging innovation, manufacturing redistribution, and elevated regulatory expectations are collectively redefining strategic priorities for logistics providers

The biopharmaceutical third-party logistics landscape is undergoing transformative shifts driven by technological maturation, regulatory recalibration, and changing manufacturing footprints. Digitalization is moving beyond pilot projects into operational core functions, with real-time telemetry, condition-based exception management, and predictive analytics enabling proactive interventions that reduce spoilage and expedite shipments.

Simultaneously, packaging innovation is reshaping cold chain economics. Active packaging solutions such as controlled atmosphere systems and advanced refrigerated containers are increasingly deployed alongside sophisticated passive insulation to create hybrid models that extend viable transit windows and reduce reliance on expedited modes. These technical advances are complemented by tighter integration between packaging design and transportation planning, which together optimize payload density and lower per-unit handling risks.

Another key vector of transformation is the strategic redistribution of manufacturing and supply nodes. The acceleration of regional manufacturing hubs and increased verticalization among biopharmaceutical firms are prompting logistics providers to reconfigure networks toward nearshoring and multi-node distribution. These shifts require flexible warehousing footprints combining ambient and cold storage capabilities and tailored transportation solutions spanning express air, standard air, sea freight, and road modalities.

Regulatory scrutiny is intensifying, and compliance expectations are expanding from documentation accuracy to demonstrable end-to-end control through digital audit trails and validated temperature control systems. As a result, providers that can demonstrate robust quality systems, validated processes, and transparent chain-of-custody reporting will capture greater trust and market preference. In short, the industry is moving toward an ecosystem where technological capability, regulatory readiness, and network adaptability determine market leadership.

Assessing how 2025 tariff adjustments have triggered nearshoring, modal optimization, enhanced customs expertise, and resilience investments across biopharmaceutical supply chains

The cumulative effects of tariff adjustments originating from United States trade policy in 2025 are materially reshaping cross-border flows and strategic logistics decision-making for biopharmaceutical supply chains. Tariff-driven cost exposure has prompted many manufacturers and logistics partners to reassess sourcing strategies, inventory postures, and modal choices in order to preserve margin and service levels while maintaining compliance with customs and trade rules.

One immediate consequence is the intensification of nearshoring discussions. Companies are increasingly evaluating whether to relocate certain production steps or hold buffer inventories in closer proximity to key markets to reduce the incidence of tariff-triggered cost spikes. This tactical shift has downstream implications for warehousing strategies, requiring flexible contract terms and the ability to scale cold and ambient storage on short notice.

Trade barriers have also incentivized modal reassessment. When tariffs raise the landed cost of ocean-shipped intermediate inputs or finished goods, organizations may switch to higher-cost but faster air transport for critical SKUs to mitigate exposure, or conversely consolidate volumes and optimize containerization strategies to amortize duties over larger shipments. Both approaches demand enhanced coordination between packaging design and transportation planning to maintain temperature integrity while managing per-shipment economics.

Customs complexity and documentation scrutiny have increased in tandem with tariff changes, elevating the importance of trade compliance expertise within third-party logistics offerings. Providers that can deliver customs brokerage competence, tariff classification advisory, and duty mitigation services add strategic value. Moreover, tariff volatility has underscored the importance of contractual flexibility around pass-through costs, hedging arrangements, and service-level adjustment clauses so that commercial relationships remain equitable under shifting trade conditions.

Beyond cost management, tariffs have accelerated investments in supply chain visibility and scenario planning. Organizations now place greater emphasis on stress-testing distribution networks against tariff escalations and simulating their operational impact on lead times, inventory days of supply, and cold chain continuity. This greater focus on resilience translates into demand for analytics-driven consulting and a willingness to invest in dual-sourcing, buffer warehousing, and modular transportation capacity that can be redeployed as trade dynamics evolve.

A detailed segmentation framework exposing how service types, temperature classifications, transport modes, end-user demands, product categories, and packaging choices jointly determine logistics strategy

Segmentation analysis reveals how service structures, temperature control requirements, transportation modes, end-user profiles, product types, and packaging choices intersect to define value propositions and operational priorities for logistics providers. When examined through the lens of service type, the market encompasses distribution management, packaging and labeling, transportation, and warehousing. Packaging and labeling itself splits into active and passive approaches, with active packaging further differentiating into controlled atmosphere solutions and refrigerated containers. Transportation subdivides into air, rail, road, and sea, with air offering express and standard options that cater to different urgency and cost trade-offs. Warehousing balances ambient storage with cold storage capabilities that must operate under validated monitoring regimes.

Temperature range segmentation drives core operational decisions because ambient, chilled, controlled room temperature, and frozen conditions each impose distinct handling, monitoring, and regulatory requirements. The chilled segment distinguishes between monitored chilled and standard chilled environments, while controlled room temperature operations are similarly differentiated by monitored and standard variants; frozen logistics separates standard frozen from ultra-frozen requirements that often necessitate specialized infrastructure.

Mode-of-transportation segmentation highlights how choice of air freight, rail freight, road transport, and sea freight affects transit time, environmental exposure, and packaging demands. Air freight options include express and standard air, road transport distinguishes between full truck load and less-than-truckload models, and sea freight differentiates between full container load and less-than-container load strategies. These modal distinctions inform optimal packaging and inventory strategies across the distribution footprint.

End-user segmentation clarifies demand heterogeneity: biopharmaceutical manufacturers, contract manufacturing organizations, contract research organizations, diagnostic laboratories, and hospitals and clinics each generate different service-level expectations and regulatory touchpoints. Hospitals and clinics further split into community hospitals and research hospitals, which diverge in procurement cadence and clinical risk tolerance.

Product-type segmentation identifies unique handling needs across cell therapies, gene therapies, monoclonal antibodies, recombinant proteins, and vaccines. Cell therapies require sub-segmentation into dendritic cell therapies and stem cell therapies, each with intense cold chain sensitivity. Vaccines divide into inactivated and live attenuated types, which carry different stability, transport, and regulatory demands. Finally, packaging type segmentation contrasts active and passive systems; active packaging includes refrigerated containers and temperature-controlled shippers while passive solutions rely on insulated boxes and thermal blankets. Together, these segmentation axes form a matrix that governs infrastructure investment, personnel training, and quality assurance protocols for third-party logistics providers.

How distinct regional infrastructure, regulatory regimes, and commercial dynamics across the Americas, EMEA, and Asia-Pacific drive differentiated network design and service priorities

Regional dynamics materially influence network design and service expectations, with each geography presenting distinct operational, regulatory, and commercial considerations. In the Americas, dense innovation clusters, advanced cold chain infrastructure, and a mature regulatory environment create demand for high-frequency express services, validated cold storage, and integrated customs expertise. Regional trade agreements and domestic manufacturing investments shape modal choices and warehouse placement, while commercial customers prioritize rapid replenishment for critical therapies and scalable temperature-controlled warehousing.

Europe, the Middle East, and Africa present a heterogeneous set of conditions. Western Europe combines strict regulatory oversight with established multimodal corridors, encouraging providers to deploy harmonized quality management systems and cross-border cold chain solutions. The Middle East functions as a hub for distribution and re-export, prompting investments in transit-oriented warehousing and resilient air connectivity. Africa introduces infrastructural and cold chain challenges that increase the importance of last-mile solutions, partnership models with local operators, and investments in passive packaging to mitigate limited refrigerated capacity.

Asia-Pacific offers a blend of high-volume manufacturing centers, rapidly expanding regional demand, and variable regulatory environments. Southeast Asia and parts of South Asia are seeing accelerated capacity build-out for both ambient and cold storage, while Northeast Asia continues to drive high-complexity exports of biologics that demand rigorous temperature control and expedited transport options. Across the region, logistics providers must balance investment in large-scale cold chain assets with agile distribution networks that can adapt to fluctuating trade flows, regulatory differences, and seasonal demand patterns.

Why market leaders succeed through a combination of digital visibility, validated cold chain assets, regulatory expertise, and flexible, scalable commercial models

Leading companies in the third-party logistics space for biopharmaceuticals are differentiating along several axes: integrated digital visibility, validated cold chain assets, regulatory and customs expertise, and flexible commercial models that accommodate clinical and commercial product nuances. Market leaders invest in telemetry platforms that generate continuous condition data and enable automated exception management, while simultaneously expanding geographically to position inventory closer to key demand centers.

Strategic partnerships and acquisition activity are common routes to quickly acquire niche capabilities, such as ultra-low temperature storage or specialized packaging engineering. Providers that combine in-house technical know-how with scalable warehousing footprints and a network of certified carriers deliver a compelling proposition for manufacturers and service organizations seeking lower risk. In addition, firms that embed trade compliance and tariff advisory into their service mix provide additional value as companies navigate complex cross-border flows.

Operational excellence remains a differentiator: companies that standardize procedures across regions, validate packaging and transport solutions, and maintain rigorous documentation practices reduce latency during regulatory inspections and audits. The ability to offer modular services-from dedicated cold rooms to managed distribution programs-enables logistics providers to address the spectrum of needs from contract research organizations to large-scale biopharmaceutical manufacturers. Ultimately, commercial success correlates with the ability to translate technical capability into predictable, auditable service performance.

Practical, high-impact actions for logistics leaders to enhance visibility, optimize packaging strategies, redesign networks for resilience, and integrate trade compliance into service delivery

Industry leaders should prioritize a set of actionable steps to build resilient, compliant, and cost-effective third-party logistics capabilities for biopharmaceutical products. First, invest in end-to-end visibility systems that provide real-time telemetry, automated exception alerts, and integrated reporting to satisfy both operational needs and regulatory requirements. Such systems reduce product loss and support rapid decision-making when deviations occur.

Second, adopt a layered packaging strategy that pairs passive and active solutions to optimize cost while protecting product integrity. By aligning packaging selection with transit modality and temperature sensitivity, organizations can extend delivery windows without consistently resorting to time-critical air shipments. This approach should be validated through protocol-driven qualification testing.

Third, re-evaluate network topology to incorporate nearshoring and multi-node distribution where appropriate. Reducing cross-border exposure and situating buffer inventory closer to demand can mitigate tariff risk and shorten lead times. However, any network redesign must be accompanied by contractual flexibility with service providers and contingency plans for capacity constraints.

Fourth, embed trade compliance and customs advisory into logistics partnerships to proactively manage tariff implications and classification risks. Providers that offer these capabilities remove a significant administrative burden from customers and improve predictability in landed cost management.

Finally, develop modular commercial offerings that permit rapid scaling between clinical and commercial phases, support ultra-cold storage needs, and provide dedicated customer success resources for high-risk product classes. Aligning commercial incentives with service reliability encourages collaborative problem-solving and long-term partnerships.

A rigorous mixed-methods research approach combining practitioner interviews, operational case reviews, selective secondary synthesis, and expert peer validation to produce actionable logistics insights

The research underpinning this analysis combines a multi-method approach that triangulates primary interviews, secondary literature synthesis, and operational case reviews to ensure robustness and relevance. Primary inputs include structured interviews with supply chain and quality executives, logistics operators, packaging engineers, and regulatory specialists, which inform qualitative assessments of capability gaps and emergent practices. These conversations formed the basis for scenario analysis and risk mapping across service types and regions.

Secondary sources were selectively reviewed to contextualize technological adoption patterns, regulatory developments, and modal cost dynamics. Operational case reviews provided granular insight into packaging qualifications, cold chain failures, and remediation strategies, enabling the identification of repeatable mitigations and best practices. Emphasis was placed on validated examples rather than anecdote, and care was taken to cross-check claims against multiple independent practitioner accounts.

To maintain analytical rigor, the methodology incorporated sensitivity testing of network and packaging assumptions, as well as peer review by subject matter experts with hands-on experience in biopharma logistics operations. The analysis avoids speculative forecasts and focuses on empirically grounded trends, observed behaviors, and practical implications for procurement and operations teams.

Limitations are acknowledged: the research emphasizes qualitative and operational insights rather than proprietary commercial metrics. Where appropriate, recommendations are framed for adaptation to specific contexts and include prompts for organizations to conduct localized validation and cost-benefit analysis prior to large-scale implementation.

Synthesis of why validated cold chain capabilities, adaptable networks, and embedded trade compliance will determine competitive advantage and operational resilience

The confluence of technological innovation, regulatory tightening, and shifting trade dynamics is accelerating the evolution of third-party logistics for biopharmaceuticals. Providers that cultivate advanced telemetry, validated packaging ecosystems, and deep regulatory and customs expertise will be best positioned to serve a market defined by complex product sensitivity and high service expectations. In this environment, tactical excellence in cold chain operations translates directly into strategic value for manufacturers and care providers alike.

Network adaptability and commercial flexibility emerge as central themes: the ability to repurpose warehousing footprints, pivot transportation modes, and offer modular service packages enables rapid response to both demand surges and policy disruptions. Companies that integrate trade compliance into their core offering reduce friction and add competitive differentiation, especially as tariff volatility and cross-border complexity persist.

Finally, the most successful logistics partners will be those that operationalize continuous improvement-systematically validating packaging, stress-testing distribution designs, and investing in workforce training to meet rising quality expectations. By translating insights into validated processes and demonstrable performance, logistics providers can reduce waste, accelerate patient access, and support the broader commercialization pathways of increasingly sophisticated biopharmaceutical therapies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of AI-driven real-time temperature monitoring solutions to ensure biologic stability during cold chain logistics
• 5.2. Expansion of specialized GDP-compliant facilities to support cell and gene therapy storage and distribution requirements
• 5.3. Implementation of digital twin technology for predictive modeling of complex biopharma supply chain disruptions
• 5.4. Collaboration between 3PL providers and regulatory bodies to streamline serialization and track-and-trace compliance
• 5.5. Development of multi-modal transportation networks integrating air, sea, and ground to optimize cold chain efficiency globally
• 5.6. Investment in sustainable cold chain packaging solutions to reduce carbon footprint and maintain product integrity over long distances
• 5.7. Adoption of blockchain-enabled platforms for enhanced transparency in biologics provenance and temperature excursion tracking
• 5.8. Rising demand for end-to-end visibility platforms integrating IoT sensors and cloud analytics in temperature-sensitive shipments
• 5.9. Strategic partnerships for last-mile delivery customized to hospital and clinical trial requirements in mRNA vaccine distribution
• 5.10. Growth of on-demand warehousing models offering scalable capacity and flexible lease terms for biopharma distribution networks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical Third Party Logistics Market, by Service Type

• 8.1. Distribution Management
• 8.2. Packaging & Labeling
  • 8.2.1. Active Packaging
    • 8.2.1.1. Controlled Atmosphere Packaging
    • 8.2.1.2. Refrigerated Containers
  • 8.2.2. Labeling Services
  • 8.2.3. Passive Packaging
• 8.3. Transportation
  • 8.3.1. Air Transport
    • 8.3.1.1. Express Air
    • 8.3.1.2. Standard Air
  • 8.3.2. Rail Transport
  • 8.3.3. Road Transport
  • 8.3.4. Sea Transport
• 8.4. Warehousing
  • 8.4.1. Ambient Storage Warehousing
  • 8.4.2. Cold Storage Warehousing

9. Biopharmaceutical Third Party Logistics Market, by Temperature Range

• 9.1. Ambient
• 9.2. Chilled
  • 9.2.1. Monitored Chilled
  • 9.2.2. Standard Chilled
• 9.3. Controlled Room Temperature
  • 9.3.1. Monitored Controlled Room Temperature
  • 9.3.2. Standard Controlled Room Temperature
• 9.4. Frozen
  • 9.4.1. Standard Frozen
  • 9.4.2. Ultra Frozen

10. Biopharmaceutical Third Party Logistics Market, by Mode Of Transportation

• 10.1. Air Freight
  • 10.1.1. Express Air
  • 10.1.2. Standard Air
• 10.2. Rail Freight
• 10.3. Road Transport
  • 10.3.1. Full Truck Load
  • 10.3.2. Less Than Truck Load
• 10.4. Sea Freight
  • 10.4.1. Full Container Load
  • 10.4.2. Less Than Container Load

11. Biopharmaceutical Third Party Logistics Market, by End User

• 11.1. Biopharmaceutical Manufacturers
• 11.2. Contract Manufacturing Organizations
• 11.3. Contract Research Organizations
• 11.4. Diagnostic Laboratories
• 11.5. Hospitals & Clinics
  • 11.5.1. Community Hospitals
  • 11.5.2. Research Hospitals

12. Biopharmaceutical Third Party Logistics Market, by Product Type

• 12.1. Cell Therapies
  • 12.1.1. Dendritic Cell Therapies
  • 12.1.2. Stem Cell Therapies
• 12.2. Gene Therapies
• 12.3. Monoclonal Antibodies
• 12.4. Recombinant Proteins
• 12.5. Vaccines
  • 12.5.1. Inactivated
  • 12.5.2. Live Attenuated

13. Biopharmaceutical Third Party Logistics Market, by Packaging Type

• 13.1. Active Packaging
  • 13.1.1. Refrigerated Containers
  • 13.1.2. Temperature Controlled Shippers
• 13.2. Passive Packaging
  • 13.2.1. Insulated Boxes
  • 13.2.2. Thermal Blankets

14. Biopharmaceutical Third Party Logistics Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Biopharmaceutical Third Party Logistics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Biopharmaceutical Third Party Logistics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Kuehne + Nagel International AG
  • 17.3.2. Deutsche Post AG
  • 17.3.3. DSV Panalpina A/S
  • 17.3.4. DB Schenker Logistics Germany AG & Co. KG
  • 17.3.5. United Parcel Service, Inc.
  • 17.3.6. FedEx Corporation
  • 17.3.7. CEVA Logistics AG
  • 17.3.8. Agility Public Warehousing Company K.S.C.P.
  • 17.3.9. Bollore SE
  • 17.3.10. Expeditors International of Washington, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)

T